Skip to main content

Dr. Danesh A. Alam, MD

Psychiatry (Psychiatry Physician)

At a glance

In the NPI registry since
2006

Licensed in Illinois since 1999, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Psychiatry Physician primary
    FL license ME97712 · IL license 036-101113 (first issued 1999; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Psychiatry per capita by county →

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Trazodone Hcl
Other prescribers in Winfield, IL
21
Fluoxetine Hcl
Other prescribers in Winfield, IL
17
Suboxone (buprenorphine hcl/naloxone hcl)
Other prescribers in Winfield, IL
12

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 4 companies reported 5 payments worth $16,767 in total to this clinician.

By type
Consulting Fee$16,679
Food and Beverage$88.25

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jul 2, 2025Eli Lilly and Company
Jul 2, 2025
Consulting Fee$11,219
Jan 3, 2025Janssen Pharmaceuticals, Inc
Jan 3, 2025
Consulting Fee
SPRAVATO · Neuroscience
$5,460

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Illinois →

Industry-funded research

Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $131,175 in research payments for these studies, mostly to the institutions running them.

  • A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD)…
    Janssen Research & Development, LLC
  • A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5
    Janssen Research & Development, LLC
  • A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inade…
    Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.)
  • An open-label, multicenter trial to assess the safety and tolerability of lumateperone as adjunctive therapy in the treatment of patients with major depressive disorder
    Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.)
  • An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
    E.r. Squibb & Sons, L.l.c. · Completed · NCT04820309
  • A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [D6-dm]/quinidine sulfate [q]) for the treatment…
    Otsuka Pharmaceutical Development & Commercialization, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Psychiatry clinicians in Winfield

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 26, 2022), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1043227200. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.